Skip to content

Evaluation of the effect of RIPC (remote ischemic preconditioning) on Migraine headache

Evaluation of the effect of RIPC (remote ischemic preconditioning) on Migraine headache in patients with migraine : a pilot study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210212050334N3
Enrollment
30
Registered
2022-05-30
Start date
2022-06-22
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine. Chronic migraine without aura, Intractable, With status migraineurs

Interventions

Intervention 1: Intervention group: The patient undergoes RIPC protocol 6 days/ week. sphygmomanometer will be fastened to the patient's arm and will be remained under the pressure of 200 mmHg for 5 m

Sponsors

Rasht University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patient have at least 5 headache attacks lasting 4–72 hours (without treatment or unsuccessful treatment) Age range 18 to 50 years Both male and female Gender The onset of migraines before menopause Ability of Patient to distinguish migraine headaches from other conditions Ability to fill out questionnaire Signed informed consent

Exclusion criteria

Exclusion criteria: Presence of underlying diseases, history of chronic diseases or kidney, liver, cardiovascular, renal, pulmonary diseases, any malignancy, autoimmunity diseases, diabetes mellitus Convulsions Menopause Head and neck trauma Existence of asthenic damage Mental disorders and major depression according to DSM4 Botox injection in the last 6 months Pregnancy and lactation Severe hypertension greater than 160/90 mm / hg Non-migraine headaches such as tension headaches that occur more than 12 times a month and cervicogenic Drug and alcohol dependency during one year prior to the study Rheumatism Migraine with aura History of off - pump surgery

Design outcomes

Primary

MeasureTime frame
Headache intensity. Timepoint: Each time after the migraine attack (day 0 -60). Method of measurement: According to the VAS index.;Migraine-induced disability. Timepoint: Days 0 and 90. Method of measurement: According to the MIDAS index.;Time of migraine start. Timepoint: At the admission. Method of measurement: Asking from patients.;Blood CGRP level. Timepoint: Days 0and 60. Method of measurement: ELISA kit.;Blood lactate level. Timepoint: ?Days 0 and 60. Method of measurement: Blood test.

Secondary

MeasureTime frame
Migraine-induced disability. Timepoint: Days 0 and 90. Method of measurement: According to the MIDAS index.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmaneh Mohammadi Roushandeh

Rasht University of Medical Sciences

mohammadi_roushandeh@gums.ac.ir+98 13 3333 5820

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026